Replies to post #227588 on Biotech Values

[DewDiligence]

ASMB +37%(!) on financing transaction (#msg-152749460). The net proceeds will be about $135M (assuming exercise of the underwriter’s option).

Plainly, some investors think HBV is an enterprising area for R&D expenditures! (Also see #msg-152014949.)